TRML VS BMEA Stock Comparison

Performance

TRML
100/100

TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

BMEA
100/100

BMEA returned 11.40% in the last 12 months. Based on SPY's performance of -13.35%, its performance is above average giving it a score of 100 of 100.

Volatility

TRML
67/100

TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

BMEA
39/100

BMEA has had a lower than average amount of volatility over the last 12 months giving it a score of 38 of 100.

Technicals

TRML

"Technicals" not found for TRML

BMEA
25/100

BMEA receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

TRML

"Earnings" not found for TRML

BMEA
10/100

BMEA has missed earnings 8 times in the last 20 quarters.

Profit

TRML

"Profit" not found for TRML

BMEA
10/100

Out of the last 15 quarters, BMEA has had 0 profitable quarters and has increased their profits year over year on 1 of them.

All score calculations are broken down here to help you make more informed investing decisions

Tourmaline Bio, Inc. Common Stock Summary

Nasdaq / TRML

Healthcare

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Biomea Fusion, Inc. Common Stock Summary

Nasdaq / BMEA

Healthcare

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Power up your portfolio